This study aimed to assess the serum level of Leucine-rich alpha-2 glycoprotein 1 (LRG1) in Acne vulgaris (AV) individuals and evaluate the effect of probiotic therapy on these serum levels.
Acne vulgaris (AV) is a common inflammatory disorder of the pilosebaceous units, characterized by the presence of inflammatory, non-inflammatory, or a combination of both types of lesions. Recent attention has turned toward biomarkers that reflect the inflammatory activity in acne and might act as indicators of disease severity, treatment response, or prognostic risk. One such candidate is Leucine-rich alpha-2 glycoprotein 1 (LRG1). Probiotics are live microorganisms that, when administered in sufficient quantities, can modulate the composition of the gut microbiota, helping reduce microbial dysbiosis, regulate the immune response, and decrease inflammatory mediators, thereby reducing systemic inflammatory burden, which is called the gut-skin-axis relationship.
Study Type
OBSERVATIONAL
Enrollment
50
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.
Benha University
Banhā, Benha, Egypt
Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level
Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level was assessed.
Time frame: 12 weeks after the therapy
Acne severity
Acne severity was assessed based on Global Acne Grading System (GASA) score is considered as 1-18 "mild," 19-30 "moderate," 31-38 "severe," and \>39 "very severe"
Time frame: 12 weeks after the therapy
Patient satisfaction
Patient satisfaction was evaluated using the Likert scale, with response options ranging from 1 = very dissatisfied to 5 = very satisfied.
Time frame: 12 weeks after the therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.